文献速递膀胱癌与上尿路尿路上皮癌

抗体药物偶联物在卡介苗暴露的非肌层浸润性膀胱癌中作用的分子探究

A Molecular Inquiry into the Role of Antibody-Drug Conjugates in Bacillus Calmette-Guérin-exposed Non-muscle-invasive Bladder Cancer.
PubMed 文献 · Eur Urol · 2021-11-01

该研究在未治疗的非肌层浸润性膀胱癌(NMIBC)肿瘤队列中,评估了卡介苗(BCG)治疗前后与抗体药物偶联物(ADC)相关基因的表达。结果显示,BCG治疗后Nectin-4、Trop-2和Her-2等多个基因表达较基线升高,但ADC靶点表达升高的肿瘤中PD-L1/PD-1表达升高者较少。作者认为BCG暴露的NMIBC基因组 landscape 具有异质性,支持在NMIBC中评估ADC。

要点

  • BCG治疗后Nectin-4、Trop-2和Her-2等ADC靶点基因表达较基线升高。
  • ADC靶点表达升高的肿瘤中,仅少数同时伴PD-L1/PD-1表达升高。
  • BCG暴露的NMIBC基因组呈异质性,支持进一步评估ADC。

核心结论

  • BCG暴露的NMIBC呈现异质性基因组 landscape,数据支持在NMIBC中评估ADC。

研究设计与样本

  • 在未治疗NMIBC肿瘤队列中,评估BCG治疗前后与ADC相关基因的表达。

主要发现

  • BCG治疗后Nectin-4、Trop-2和Her-2等多个基因表达较基线升高。
  • ADC靶点表达升高的肿瘤中,仅少数同时出现PD-L1/PD-1表达升高。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The treatment landscape for advanced urothelial cancer has changed dramatically owing to the US Food and Drug Administration approval and introduction of antibody-drug conjugates (ADCs), including enfortumab vedotin and sacituzumab govitecan. Efforts have begun to use these therapies in earlier disease states, specifically bacillus Calmette-Guérin (BCG)-unresponsive non-muscle-invasive bladder cancer (NMIBC). We assessed gene expression associated with these newly approved therapies in a novel cohort of treatment-naïve NMIBC tumors before and after BCG therapy. Multiple genes, including Nectin-4, Trop-2, and Her-2, exhibited increased expression after BCG therapy compared to baseline. However, few of the tumors with increased expression of ADC targets also exhibited increased PD-L1/PD-1 expression. Taken together, these data demonstrate the heterogeneous genomic landscape of BCG-exposed NMIBC, and provide evidence supporting the evaluation of ADCs in NMIBC. PATIENT SUMMARY: We evaluated the potential role of targeted therapies that have been approved in the USA for advanced non-muscle-invasive bladder cancer (NMIBC) that has recurred after treatment with bacillus Calmette-Guérin (BCG). By assessing levels of specific genes and proteins linked to the targeted therapies, we demonstrate that there is rationale for further evaluation of these therapies in NMIBC.

来源:Eur Urol,查看原文。版权归原作者所有。

引用

  1. Choi W, Lombardo K, Patel S, et al. A Molecular Inquiry into the Role of Antibody-Drug Conjugates in Bacillus Calmette-Guérin-exposed Non-muscle-invasive Bladder Cancer. Eur Urol. 2021. PMID: 34736796. doi:10.1016/j.eururo.2021.10.009

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。